Medically reviewed by Dr. C.H. Weaver M.D. Medical Editor 10/2020
Myelodysplastic syndromes (MDS) are a group of diseases marked by abnormal production of blood cells by the bone marrow. Healthy bone marrow produces immature blood cells—called blasts—that then develop into red blood cells, white blood cells, and platelets. MDS disrupts this normal process so that the bone marrow is overactive, producing many immature cells. These blasts, however, do not fully develop into mature blood cells. As a result, patients with MDS have fewer mature blood cells, and the cells produced may be abnormal and not function properly.
Any or all blood cell types may be affected by MDS, which is different from leukemia in which only white blood cells are overproduced. The direct effects of MDS may include:
- Anemia and fatigue if red blood cells counts are low
- Increased risk of infection if white blood cell counts are low
- Compromised ability to control bleeding if platelets counts are low
Failure of the bone marrow to produce normal cells is a gradual process. As such, MDS is primarily a disease of the aging and most patients are over 65 years of age. Some patients experience prolonged survival with MDS while approximately one-third will have their disease progress to acute myeloid leukemia (AML). AML that develops from MDS is a difficult disease to treat.
Treatments for MDS may consist of supportive care through administration of growth factors to stimulate immature cells to development into mature blood cells, chemotherapy, immunotherapy and newer precision caner medicines to destroy the abnormal cells and or replacement of the damaged bone marrow with healthy cells that develop into blood cells, a procedure called stem cell transplantation
About this MDS Treatment Information
The information contained on this site is a general overview of treatment for MDS. Treatment may consist of growth factors, chemotherapy with or without stem cell transplantation, targeted therapy, or a combination of these treatment techniques. In some cases, participation in a clinical trial utilizing new, innovative therapies may provide the most promising treatment.
Circumstances unique to each patient’s situation may influence how these general treatment principles are applied. This is intended to help educate patients about their treatment options and to facilitate a mutual or shared decision-making process with their treating physician.
Signs & Symptoms of Myelodysplastic Syndrome
Any or all blood cell types may be affected by MDS and the signs and symptoms that an individual may experience result from MDS direct effects on bone marrow blood cell production.
- Decreased red blood cell production Anemia Fatigue or feeling tired Shortness of breath Pale skin
- Decreased white blood cell production Infections
- Decreased platelet production Easy bruising Petechiae (flat, pinpoint spots under the skin caused by bleeding). Inability to control bleeding
Anything that increases your chance of getting a disease is called a risk factor. Having a risk factor does not mean that you will get colon cancer and not having risk factors doesn’t mean that you will not get cancer, it simply means that you are at greater risk than normal to develop the cancer.
Risk factors for MDS include the following:
- Past treatment with chemotherapy or radiation
- Being exposed to certain chemicals, pesticides, fertilizers and solvents such as benzene.
- Being exposed to heavy metals (mercury or lead)
- Older age is also a risk factor for most cancers. The chance of getting cancer increases as you get older.
The cause of myelodysplastic syndromes in most patients is not known.
Normal Blood Cell Production
In order to better understand MDS and its treatment, a basic understanding of normal blood cell production is useful. Normal blood is made up of fluid called plasma and three main types of blood cells–white blood cells, red blood cells, and platelets. Each type of blood cell has a specific function:
- White blood cells, also called leukocytes, help the body fight infections and other diseases.
- Red blood cells, also called erythrocytes, make up half of the blood’s total volume and are filled with hemoglobin, which picks up oxygen from the lungs and carries it to the body’s organs.
- Platelets, or thrombocytes, help form blood clots to control bleeding.
Blood cells are produced inside the bones in a spongy space called the bone marrow. The process of blood cell formation is called hematopoiesis. All blood cells develop from one common cell type, called a stem cell. Stem cells become mature blood cells by a process called differentiation. Immature blood cells are called blasts. Blasts grow or differentiate into mature red blood cells, white blood cells, and platelets. Once they are fully developed, these cells are released into the blood where they circulate throughout the body and perform their respective functions.
In healthy individuals, there are adequate stem cells to continuously produce new blood cells and mature blood cells are produced in a continuous and orderly fashion. MDS disrupts this normal process resulting in many blasts and few mature, healthy blood cells.
Diagnosis & Tests Used in Myelodysplastic Syndrome
In order to diagnose MDS and plan treatment, a physician must evaluate a patient’s bone marrow cells to determine the specific type of MDS. The cells are removed through a technique called a bone marrow aspiration and biopsy, which uses a large needle to withdraw cells directly from the bone marrow.
In addition to evaluating the appearance of the bone marrow, cells, and number of blasts in the biopsy specimen, additional special laboratory tests are conducted on the sample cells to determine whether there are abnormalities in the DNA of the blood cells. DNA contains the genetic code for the cell, which can be thought of as the instructions for what the cell looks like, what it does, and how it grows. Most forms of MDS and leukemias are characterized by specific abnormalities. Identifying these provides useful information about the prognosis, or duration of survival.
Additional tests that may be done on cells from the bone marrow aspiration and biopsy.
- Fluorescence in situ hybridization (FISH) looks at the actual DNA or chromosomes. Pieces of DNA that contain a fluorescent dye are made in the laboratory and added to cells or tissues on a glass slide. When these pieces of DNA bind to specific genes or areas of chromosomes on the slide, they light up when viewed under a microscope with a special light.
- Immunocytochemistry uses antibodies to check for certain antigens which can tell the difference between myelodysplastic syndromes, leukemia, and other health conditions.
- Immunophenotyping is used to identify cells, based on the types of markers on the surface of the cell.
- Flow cytometry measures the number of cells in a sample, the percentage of live cells in a sample, and certain characteristics of cells, such as size, shape, and the presence of tumor on the cell surface.
Types of Myelodysplastic Syndrome
There are several different types of MDS, which are classified by how the abnormal cells that were removed from the bone marrow appear under the microscope and how many blasts can be identified. MDS is classified into five different diseases characterized by ineffective blood cell production in the bone marrow and varying rates of progression to acute leukemia. Following is a description of the five classifications:
Refractory Anemia (RA): Patients have low blood counts, bone marrow blasts are less than 5%, and sideroblasts (iron containing cells) are less than 15%. The average survival is approximately 43 months but can be influenced by specific chromosomal abnormalities.
Refractory Anemia with Ringed Sideroblasts (RARS): Patients have low blood counts, bone marrow blasts are less than 5%, and sideroblasts are greater than 15%. The average survival is 55 months but can be influenced by specific chromosomal abnormalities.
Refractory Anemia with Excess Blasts (RAEB): Patients have low blood counts, 1-5% blasts in the blood, and bone marrow blasts between 5 and 20%. The average survival is 12 months but can be influenced by specific chromosomal abnormalities.
Refractory Anemia with Excess Blasts in Transition (RAEBt): Patients have low blood counts, over 5% blasts in the blood or cells in the blood containing an abnormality referred to as Auer rods, and bone marrow blasts between 20 and 30%. The average survival is 5 months but can be influenced by specific chromosomal abnormalities.
Chronic Myelomonocytic Leukemia (CMML): Blood cells called monocytes make up more than 1,000 ml in the blood and patients have less than 5% blasts. Bone marrow blasts are less than 20% and the average survival is 30 months but can be influenced by specific chromosomal abnormalities.
Myelodysplastic Syndromes - A Survivors Journey
by Diana Price
It began suddenly, with swelling in her hands and feet that quickly became extremely painful. Joan Banich, then 42, who all her life had avoided seeing doctors because of a pathological fear of blood and needles, couldn’t avoid it any longer.
“It took five people to hold me down for the blood test,” recalls Joan, of Campbell, California. The doctor took one look at the test results and referred her to a hematologist, who quickly diagnosed myelodysplastic syndrome (MDS).
Myelo-what? Like most newly diagnosed patients, Joan had never heard of MDS, a disorder in which bone marrow fails to make enough healthy blood cells. The American Cancer Society estimates that about 12,000 Americans are diagnosed with MDS every year. As a relatively young woman, Joan did not fit the profile of a typical MDS patient. The disease is rare in people under 60 and more common in men than in women.
MDS and Blood: A Quick Primer
Myelodysplastic is derived from Greek: myelo means “marrow,” dys means “difficult” or “disordered” (as in dysfunctional and dyslexic), and plastic means “capable of being formed or molded.” Syndrome, also from Greek, means “a group of symptoms that occur together and characterize a disease.” Because there are multiple types of MDS, many doctors refer to the condition in the plural: “myelodysplastic syndromes.”
The bone marrow (the soft tissue inside bones) is a factory for making blood cells. Whole blood contains three types of cells:
- Red cells contain hemoglobin, a protein that keeps the body supplied with oxygen.
- White cells form a key part of the body’s immune system, its defense against infection.
- Platelets help the blood to clot.
A blood cell’s life span ranges from about nine days for platelets to about four months for red cells. Healthy bone marrow is always making new blood cells to replace the old ones. When it doesn’t, immature cells called blasts may build up in the marrow but fail to develop into mature blood cells. In healthy bone marrow, fewer than 5 percent of the blood cells are blasts. MDS is diagnosed when 5 to 20 percent of the blood cells in the bone marrow are blasts and counts of at least one type of blood cell are below normal, or when fewer than 5 percent of the blood cells are blasts but the cells appear abnormal.
MDS and Leukemia
When blasts constitute at least 20 percent of the blood cells in the bone marrow, the diagnosis changes from MDS to leukemia.
“MDS is really a precursor disease to leukemia, although in many patients it never progresses to leukemia,” explains David Steensma, MD, a hematologist-oncologist at Dana-Farber Cancer Institute in Boston.
Some doctors debate whether MDS is cancer, adds Dr. Steensma. “MDS differs from cancer in that it does not spread to other organs and it may remain stable for many years without treatment—behavior more typical of a pre-cancerous condition than a cancer.” Both the World Health Organization and the National Cancer Institute, however, recognize MDS as a form of blood cancer.
In 2003, when Joan was diagnosed with MDS, no drugs had yet been approved in the United States to treat it. The standard treatment was transfusions of healthy blood cells to replace those not being made in the patient’s bone marrow.
“I would get a transfusion every three to six weeks,” she recalls. To minimize the disruption of their family life—she and her husband, Dave Keller, have a daughter, Atley, who was then 10—she arranged to get her transfusions at night. “I would go to the hospital overnight, after Atley was in bed, and be home for breakfast,” she says.
The first drug approved to treat MDS became available in 2004; two others soon followed. Joan’s doctors tried two of the new agents, to little apparent effect at first. She continued to need blood transfusions. “Then, after I stopped taking [the drugs], I went for more than two and a half years without needing transfusions or having to be hospitalized for complications,” she says.
Immunotherapy May Improve Treatment of Rectal Cancer
Immunotherapy May Improve Treatment of Rectal Cancer
The CA 125 “tumor associated protein” or “tumor marker”
Answers to frequently asked questions about CA 125.
Bone Marrow Transplant
In December 2010 tests revealed that Joan’s red blood cell count was extremely low, and a biopsy showed scar tissue in her bone marrow. This was bad news. “My doctors said I should have a bone marrow transplant within six months,” she recounts.
A bone marrow transplant replaces the patient’s unhealthy blood-forming stem cells—the “parents” of red cells, white cells, and platelets—with healthy ones from a donor. Although it represents the only hope of curing MDS, the procedure carries many risks (see sidebar).
Joan was fortunate to quickly find a matching donor in the National Marrow Donor Registry (see sidebar). She will celebrate the one-year anniversary of her transplant in June 2012. She takes medication to keep the donated blood cells from attacking her own cells, a common transplant complication. “All things considered, I’m doing well,” she says.
For 23-Year Survivor, Positive Attitude Is Key
“The doctors told me I had aplastic anemia and I had three months to three years to live.”
It was 1989, and Norma Good’s blood tests had just come back abnormal. She was 57.
That prognosis turned out to be a wee bit off: Norma celebrated her eightieth birthday in January 2012.
Norma says she owes her life to a clinical trial at the National Institutes of Health (NIH) in Bethesda, Maryland, that was investigating growth factors to stimulate blood cell production.
For three and a half years, she traveled to NIH from her home in Ohio for growth factor injections, while going to her local hospital every 10 days or so for blood transfusions. The first two growth factors the NIH doctors tried had no effect, but after three months on the third one, Neupogen® (filgrastim), Norma’s blood counts began to inch back up to levels close to normal.
About 18 months after joining the NIH trial, Norma got a new diagnosis: MDS, with a genetic abnormality called the 5q deletion (meaning that a piece of chromosome 5 was missing in her bone marrow cells).
“My last blood transfusion was in September 1992,” she says. “I haven’t needed one since.” She still gets her blood counts checked every three months, however.
An active volunteer with the Aplastic Anemia & MDS International Foundation, Norma frequently counsels newly diagnosed MDS patients. Nowadays, she says, because of quicker diagnosis and new medications, “most of the patients I talk with have never had to have a blood transfusion.”
The secret to her long survival with this chronic illness, Norma says, is a positive attitude. “There will be a tomorrow as long as you have a strong desire for one. Medicine can only do part of it.”
Tips for New Patients
For patients facing a new diagnosis of MDS, Joan offers the following tips.
- “You can have a more normal life than you might expect. What’s normal changes, but you learn to live with it.”
- Do your research, but be aware that information found on the Internet may be misleading or inaccurate. Learn to identify and use reputable websites.
- Ask for and keep copies of medical records, prescriptions, and lab test results.
- Take a notebook and a list of questions with you on doctor visits.
- Be an active partner in your care.
- Join the MDS community at cancerconnect.com/groups/leukemia-aml-or-mds/
Treatment Options for MDS: It’s Complicated
“It can be a challenge to decide on the best initial treatment” for a patient newly diagnosed with MDS, says David Steensma, MD, a hematologist-oncologist at Dana-Farber Cancer Institute in Boston. The following are just some of the factors that doctors must consider when selecting a treatment option.
Subtype. Depending on the classification system used, MDS has five or seven subtypes, identified by blood and bone marrow findings.
Genetic abnormalities. More than 20 genetic abnormalities have been identified so far in patients with MDS, and many more are likely still unidentified. Most of these abnormalities occur randomly: people don’t inherit them from their parents or pass them on to their children. MDS very rarely runs in families. Some genetic changes confer a higher risk that MDS will progress to leukemia, while others don’t have any effect on progression.
Number of blast cells. A higher proportion of blasts in the bone marrow at diagnosis (e.g., more than 10 percent) indicates a higher risk of progression to leukemia.
Number of low blood counts. A patient with only one low blood count probably has a better outlook than one with low counts of all three types of blood cells (red cells, white cells, and platelets), says Dr. Steensma.
Age and general health. Doctors might propose a different treatment strategy for a young, otherwise healthy patient than for an older patient with other chronic health problems in addition to MDS.
Vidaza® (azacitidine) became the first drug approved by the US Food and Drug Administration (FDA) to treat MDS in 2004. It was followed by Revlimid® (lenalidomide) in 2005 and Dacogen® (decitabine) in 2006.
None of these drugs is a cure for MDS, says Mikkael Sekeres, MD, a hematologist-oncologist at Cleveland Clinic’s Taussig Cancer Center. Vidaza and Dacogen both slow the progression of MDS to leukemia and are most helpful for patients at high risk of that progression, he explains. In a 2009 study, MDS patients treated with Vidaza lived about nine months longer, on average, than patients not treated with Vidaza.1
Revlimid is approved to treat a subset of MDS patients who have a genetic abnormality called the 5q deletion, in which a piece of chromosome 5 is missing in the patient’s bone marrow cells. (Chromosomes are “packets” of DNA, the material that carries genes.)
Chemotherapy drugs and growth factors—drugs that stimulate the body to make more blood cells—may also be used to treat MDS, although they are not FDA-approved to do so.
The keys to improving MDS treatment in the future lie in combining drugs and in tailoring treatment to a patient’s own genetic profile, says Dr. Sekeres.
“Trials are now under way to find out if we can improve treatment effectiveness by using more than one drug,” he says. “The next frontier is to use genetic abnormalities to predict which drug or drug combination may be most effective for an individual.”
1.Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, Phase III study.Lancet Oncology. 2009;10(3):223-32.
A Match for Life
A successful bone marrow transplant is currently the only cure for MDS, but it’s a high-risk option.
“For about one-third of patients, a transplant is curative,” says David Steensma, MD, a hematologist-oncologist at Dana-Farber Cancer Institute in Boston. “Another one-third of patients survive the transplant procedure, but the disease comes back. And, sadly, the remaining one-third of patients succumb to complications from the transplant.”
Candidates for a transplant must be in excellent general health. “We’ve done transplants in patients as old as the midseventies if their health is otherwise excellent,” says Dr. Steensma.
The next hurdle is finding a compatible donor. About three in 10 patients have a compatible donor in their family, usually a sibling. The other option is to seek a donor through the Be The Match Registry (formerly the National Marrow Donor Program registry).
The registry “can find a compatible donor for about 70 percent of patients who are of European descent,” says Dr. Steensma. For people of other ethnicities, finding a match may be more difficult because of a shortage of minority donors.
Another barrier is that health insurance may not cover all of the costs associated with a transplant. Be The Match Foundation, in addition to maintaining the marrow donor registry, may be able to offer financial assistance.
The leading provider of social network connecting cancer patients